We maintain our fair value estimate of $187 per share. Xywav (for excessive daytime sleepiness), Epidiolex (for childhood epilepsy), and Rylaze (for leukemia) have continued to be Jazz’s primary ...

SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for ...

SpringWorks Therapeutics is the perfect case study for rescuing a discontinued assets. It’s time to repeat the process for ...

The Trump administration has started rehiring some of the FDA employees it fired last week, the latest chapter in a haphazard ...

DelveInsight's Advanced Therapy Medicinal Products Market Insights report provides the current and forecast market analysis, ...

Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...

Health experts have slammed the FDA as 'corrupt' and 'in bed with Big Pharma' after its former drug chief Dr Patrizia ...

Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...

Pfizer appoints Patrizia Cavazzoni as chief medical officer, the U.S. delays the definition of 'healthy' on labels, issues ...

Pfizer has appointed former Patrizia Cavazzoni, MD, former director of the FDA's Center for Drug Evaluation and Research, as its new chief medical officer, Bloomberg reported Feb. 24. Dr. Cavazzoni, ...

Recent developments in the health sector include Pfizer appointing Patrizia Cavazzoni as Chief Medical Officer and Amgen ...

HHS secretary RFK Jr. said that he would “shut the revolving door to reestablish public trust” in the department.